UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

September 10, 2026
(Date of earliest event reported)

LABCORP HOLDINGS INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	**1-11353**	**99-2588107**
(State or other jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

358 South Main Street **Burlington , North Carolina**	**27215**
(Address of principal executive offices)	(Zip Code)

(Registrant's telephone number including area code) **336-229-1127**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of exchange on which registered
Common Stock, $0.10 par value	**LH**	**New York Stock Exchange**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Labcorp Holdings Inc. (the "Company") (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today hosted its 2026 Investor Day ("Investor Day"), where the company provided an in-depth review of its growth strategy, innovation roadmap, and long-term financial outlook.

In connection with Investor Day, the Company issued a press release that, among other things, discussed its business strategy, reaffirmed its full-year 2026 guidance, and provided its long-term financial outlook through 2029. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein.

The Investor Day presentation used by members of the Company's executive leadership team, which includes information regarding the matters discussed by the Company at its Investor Day and in the press release, has been posted on the Labcorp Investor Relations website at ir.labcorp.com. In addition, a copy of this presentation is furnished as Exhibit 99.2 hereto and incorporated by reference herein.

The information in this Current Report on Form 8-K (including the exhibits attached hereto) shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K (including the exhibits attached hereto) shall not be deemed incorporated by reference into any filing or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing or document.

Item 9.01. Financial Statements and Exhibits.

Exhibit	Exhibit Name
Exhibit 99.1	Press Release dated September 10, 2026 issued by Labcorp Holdings Inc.
Exhibit 99.2	Investor Day Presentation, dated September 10, 2026
Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABCORP HOLDINGS INC.
Registrant

Date: September 10, 2026	By:	/s/KATHRYN W. KYLE
		Kathryn W. Kyle
		Executive Vice President, Chief Legal Officer and Corporate Secretary

Media
Racquel White
Media@Labcorp.com

Investors
Dewey Steadman
Investor@Labcorp.com

Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day

- Reaffirms full-year 2026 guidance
- Provides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to 11.5%
- Outlines strategic growth priorities driven by a differentiated platform powered by science, technology and global scale
- Presents long-term value creation framework driven by sustainable growth, strong cash flow generation and disciplined capital deployment

BURLINGTON, N.C., (Sept. 10, 2026) — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today will host its 2026 Investor Day at 9 a.m. ET, where the company will provide an in-depth review of its growth strategy, innovation roadmap and long-term financial outlook. The event will highlight Labcorp's unique position at the intersection of diagnostics, biopharma, science and technology and how the company is creating long-term value for customers and shareholders.

“Labcorp has never been more relevant than it is today,” said Adam Schechter, Chairman and CEO of Labcorp. “The healthcare landscape is being transformed by scientific innovation, personalized medicine and consumer-directed care, and the strengths of Labcorp will help shape the future of healthcare. Labcorp's growth strategy supports our expectation for above-market performance and underpins our long-term outlook through 2029 of compound annual growth of 5% to 8% in revenue and 8.5% to 11.5% in adjusted earnings per share.”

Strategic Priorities Focused on High-Growth Areas
At Investor Day, Labcorp will highlight the four strategic priorities that are driving its next phase of growth and strengthening its leadership position across the healthcare ecosystem. These priorities are:

- **Leading in specialty testing** through continued innovation in oncology, neurology, autoimmune diseases and women’s health.
- **Being a partner of choice** for health systems and leading pharmaceutical companies through differentiated scientific and operational capabilities.
- **Driving personalized health solutions** using science and insights to help develop therapies, inform therapy selection and deliver tailored experiences at scale.
- **Shaping the company’s future** through advanced technology, including artificial intelligence and robotics.

Long-Term Financial Outlook
In addition to reaffirming its 2026 guidance, Labcorp will discuss its outlook through 2029. Specifically, the company expects to achieve:

- Compound annual revenue growth between 5% and 8%
- Adjusted operating margin expansion between 75 and 150 basis points by the end of 2029
- Compound annual adjusted EPS growth between 8.5% and 11.5%
- Compound annual free cash flow growth in line with adjusted earnings growth

“Our confidence in this outlook is grounded in a proven record of delivering on our commitments and a disciplined value creation framework that converts growth into earnings, cash flow and shareholder returns,” said Julia Wang, Executive Vice President and Chief Financial Officer.

Webcast
A live webcast of the event will be available through the Labcorp Investor Relations website beginning at 9 a.m. ET. A replay of the webcast and supporting materials will be available after the conclusion of the event.

Guidance for 2026

Labcorp is affirming 2026 full-year guidance, last updated on July 30, 2026. The following guidance assumes foreign exchange rates effective as of June 30, 2026. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends.

	2026 Guidance	
	Low	High
Revenue		
Labcorp Enterprise [1] [2]	$14,710	$14,827
Growth [3]	5.4%	6.3%
Diagnostics Laboratories	$11,450	$11,532
Growth [3]	5.3%	6.0%
Biopharma Laboratory Services [4]	$3,269	$3,300
Growth [3]	5.5%	6.5%
Adjusted EPS	$18.10	$18.55
Free Cash Flow	$1,240	$1,360

(1) 2026 Enterprise guidance includes an impact from foreign currency translation of 0.4%.

(2) Enterprise level revenue is presented net of intercompany transaction eliminations.

(3) Growth based on 2025 Enterprise revenue of $13,952 million, Diagnostics Laboratories revenue of $10,876 million, and Biopharma Laboratory Services revenue of $3,098 million.

(4) 2026 Biopharma Laboratory Services guidance includes an impact from foreign currency translation of 1.5%.

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

Use of Adjusted Measures

The company has provided in this press release “adjusted” financial information that has not been prepared in accordance with GAAP, including adjusted EPS (or adjusted net income per share), adjusted operating margin, and free cash flow. Moreover, the company is not able to provide reconciliations of these adjusted measures on a forward-looking basis because it is unable to predict, without unreasonable effort, certain components thereof. As such, any associated estimate and its impact on these measures could vary materially, and the company cannot address the probable significance of unavailable information. The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company’s operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the company’s financial results with the financial results of other companies.

Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures prepared in accordance with GAAP, and these adjusted measures may be different from and not directly comparable to the measures presented by other companies.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidance, the long-term financial outlook, and the long-term capital deployment strategy, and related assumptions of each, (ii) the impact of various factors on operating and financial results, including global economic and market conditions, on the company's businesses, operating results, cash flows, and/or financial condition, (iii) current and future offerings, capabilities, and business strategies, including those related to high-growth specialty areas, (iv) expected savings, synergies and other benefits to the company, customers or patients from acquisitions and other transactions, partnerships, company initiatives and investments, (v) the use of technology, including the use of artificial intelligence (AI), and expected operational efficiencies, revenue growth, impacts on customer and patient experience and access, and other benefits from the use of such technologies, and (vi) opportunities for future growth.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the failure to receive tax-free treatment with respect to the spin-off of the company’s former Clinical Development and Commercialization Services business for U.S. federal income purposes; (ii) the impact of spin-off related items; (iii) personnel costs and potential difficulties with employee relations and retention; (iv) the trading price of the company's stock, competitive actions and other unforeseen changes and general uncertainties in the marketplace; (v) the impact of changes to existing or adoption of new laws and regulations applicable to the company, including healthcare reform, or changes to the interpretation and application of such laws and regulations; (vi) customer preferences and purchasing decisions, including changes in payer regulations or policies; (vii) adverse actions of governmental and third-party payers; (viii) changes in testing guidelines or recommendations; (ix) the impact of global geopolitical events; (x) the effect of public opinion on the company's reputation; (xi) adverse results in material litigation matters; (xii) failure to maintain or develop customer relationships; (xiii) the company's ability to develop or acquire new products and adapt to technological changes; (xiv) failures of, or adverse events relating to, the company’s information technology systems, programs, or processes or the company’s data security; (xv) the impact of potential losses under repurchase agreements; (xvi) adverse weather conditions; (xvii) the number of revenue days in a financial period; (xviii) inflation; (xix) increased competition; and (xx) the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading “MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS”.


labcorp
INVESTOR DAY 2026
Driving growth and value through
SCIENCE & INNOVATION

Cautionary Statement Regarding Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidance, the long-term financial outlook, and the long-term capital deployment strategy, and related assumptions of each, (ii) the impact of various factors on operating and financial results, including global economic and market conditions, on the company's businesses, operating results, cash flows, and/or financial condition, (iii) current and future offerings, capabilities, and business strategies, including those related to high-growth specialty areas, (iv) expected savings, synergies and other benefits to the company, customers or patients from acquisitions and other transactions, partnerships, company initiatives and investments, (v) the use of technology, including the use of artificial intelligence (AI), and expected operational efficiencies, revenue growth, impacts on customer and patient experience and access, and other benefits from the use of such technologies, and (vi) opportunities for future growth.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the failure to receive tax-free treatment with respect to the spin-off of the company's former Clinical Development and Commercialization Services business for U.S. federal income purposes; (ii) the impact of spin-off related items; (iii) personnel costs and potential difficulties with employee relations and retention; (iv) the trading price of the company's stock, competitive actions and other unforeseen changes and general uncertainties in the marketplace; (v) the impact of changes to existing or adoption of new laws and regulations applicable to the company, including healthcare reform, or changes to the interpretation and application of such laws and regulations; (vi) customer preferences and purchasing decisions, including changes in payer regulations or policies; (vii) adverse actions of governmental and third-party payers; (viii) changes in testing guidelines or recommendations; (ix) the impact of global geopolitical events; (x) the effect of public opinion on the company's reputation; (xi) adverse results in material litigation matters; (xii) failure to maintain or develop customer relationships; (xiii) the company's ability to develop or acquire new products and adapt to technological changes; (xiv) failures of, or adverse events relating to, the company's information technology systems, programs, or processes or the company's data security; (xv) the impact of potential losses under repurchase agreements; (xvi) adverse weather conditions; (xvii) the number of revenue days in a financial period; (xviii) inflation; (xix) increased competition; and (xx) the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".

Use of Adjusted Measures

The company has provided in this presentation "adjusted" financial information that has not been prepared in accordance with GAAP, including adjusted EPS (or adjusted net income per share), adjusted operating margin, and free cash flow. Moreover, the company is not able to provide reconciliations of these adjusted measures on a forward-looking basis because it is unable to predict, without unreasonable effort, certain components thereof. As such, any associated estimate and its impact on these measures could vary materially, and the company cannot address the probable significance of unavailable information.

The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company's operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the company's financial results with the financial results of other companies.

Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures prepared in accordance with GAAP, and these adjusted measures may be different from and not directly comparable to the measures presented by other companies.

Agenda

Opening	Dewey Steadman
Welcome	Adam Schechter
Diagnostics	Bryan Vaughn
Biopharma Laboratory Services	Dr. Brian Caveney
BREAK	
Specialty Diagnostics	Dr. Shak Ramkissoon
Technology and Innovation	Dr. Bola Oyegunwa
Long-Term Financial Outlook	Julia Wang
BREAK	
Q&A	All Speakers



Welcome

Adam Schechter
Chairman and Chief Executive Officer


Labcorp has never been more important
Laboratory insights power better health, breakthrough therapies, and personalized care to improve outcomes and build a more sustainable healthcare system
labcorp
INVESTOR DAY 2026
©2026 Labcorp. All rights reserved.
7

Healthcare is entering a new era

Growing and aging population

Personalized medicine advancing quickly

Consumers taking on their wellness and health

Novel science and innovation driving drug development

Advanced technology transforming healthcare

Labcorp is focused on the key trends driving the future of healthcare

Market forces magnify the importance of Labcorp

As healthcare becomes

More data-driven
More personalized
More technology enabled
More consumer-friendly

Laboratory services and insights are even more essential for

Wellness and prevention
Early disease detection
Treatment selection
Therapy monitoring

Improving health and improving lives, while reducing healthcare costs

Labcorp is ready for this moment

Labcorp is a global leader in laboratory services

BIOPHARMA LABORATORY SERVICES
Early Development | Central Laboratory Services

DIAGNOSTICS



PREVENTION → DIAGNOSIS → THERAPY SELECTION → TREATMENT → MONITORING

An interconnected ecosystem where insights, partnerships, scientific expertise, and innovation reinforce one another, creating a differentiated competitive advantage

An experienced, focused, mission-driven team

MISSION

Improve health and improve lives

VALUES

Md Mission Driven	**Cc** Customer Centered	**In** Innovative	**Ag** Agile	**Oe** Operationally Excellent

Adam Schechter
Chairman and Chief Executive Officer

Brian Caveney, MD
President, Biopharma Laboratory Services and Chief Medical and Scientific Officer

Anita Graham
Chief Human Resources Officer

Kathryn Kyle
Chief Legal Officer and Corporate Secretary

Jon Meltzer, PhD
Chief Operations Officer

Bola Oyegunwa, PhD
Chief Information and Technology Officer

Amy Summy
Chief Marketing Officer

Bryan Vaughn
President, Diagnostics

Julia Wang
Chief Financial Officer

Science and innovation with global scale

1,200[1]
Scientists and physicians

1,000
Publications and presentations

6,500
Tests on our menu

100+
Innovative tests launched/year

>50
Major laboratories globally

85%
FDA drug and therapeutic product approvals supported

750M
Tests performed annually

400,000
Patients in clinical trials across 100+ countries

1. All figures are for 2025, rounded.

Trusted partner to customers across the health ecosystem[1]

BIOPHARMA

20 of top 20 global pharma[2]
Over **2,400** active clinical studies

HOSPITALS and HEALTH SYSTEMS

12 acquisitions since 2023
4,000 hospitals nationwide

PROVIDERS

>90% trust Labcorp
>550,000 physicians use Labcorp

PAYERS

100% renewal rate on material managed care plans[3]
90% of all managed care lives[3]

CONSUMERS

76 million consumers served[4]
Net Promoter Score of **70**[4]

1. Figures except Hospitals and Health Systems acquisitions and Managed Care renewal rates are rounded.
2. Based on 2025 internal sales data.
3. Payer renewal figure is from 2025-July 2026.
4. Figure represents consumers, including patients, served in 2025. Net Promoter Score is based on data from Jan-June 2026.

Utilizing advanced technology to power innovation and drive performance

Improving Customer Experiences

Enhancing Productivity

Transforming Our Business

Strategic priorities focus on high-growth areas

Labcorp's strategic priorities focus on high-growth areas

Lead in specialty testing

Be the partner of choice for health systems and leading pharma

Drive personalized health solutions

Shape our future through innovation and technology, including AI and robotics

Our long-term outlook is compelling

Long-Term Outlook 2026 – 2029

REVENUE	MARGIN EXPANSION	ADJUSTED EPS GROWTH	FREE CASH FLOW
5% - 8% CAGR	**75 - 150** bps	**8.5% - 11.5%** CAGR	In line with adjusted earnings growth

Key takeaways

Consistent track record of delivering strong performance

Tremendous growth opportunities ahead

A differentiated platform powered by science, technology and global scale

Compelling long-term outlook

INVESTOR DAY 2026

Diagnostics: The next era of healthcare runs on diagnostic insights

Bryan Vaughn
President, Diagnostics

Overview

Large and growing market opportunity backed by proven track record

Differentiated scale and network, amplified by technology

Multiple pathways for sustainable growth

Positioned to lead as science and technology drive change

Meaningful growth opportunity in a large, growing industry

U.S. DIAGNOSTICS INDUSTRY SIZE[1]



Annual growth rate 1% - 3%

MARKET TAILWINDS

1. Figures are rounded.

Track record of above-market revenue growth

DIAGNOSTICS REVENUE GROWTH

7% CAGR



KEY DRIVERS OF SUSTAINED PERFORMANCE

- Test and accession volume growth
- Organic expansion and strategic M&A
- Shift towards specialty testing
- Diversified payer and channel mix

1. Midpoint of FY 2026 guidance previously issued on July 30, 2026; see appendix for more information.

A differentiated network connecting healthcare

90% U.S. lives covered in network	**>90%** Trust among providers
9,200+ Patient access points	**22M** Logistics stops per year
40K+ EMR / EHR interface connections	**48** Core and esoteric labs across the U.S. and Canada
6,500 Tests in portfolio	**100+** Innovative tests launched / year

We inform what's next in healthcare through...

175M+ patient interactions annually

750M tests performed annually

1. All figures are for 2025, rounded.

Amplifying our impact through technology and insights

BETTER EXPERIENCES

- Patient and provider AI agents
- Optimized patient access
- Seamless digital engagement

SMARTER OPERATIONS

- Optimized logistics network
- Automated specimen flows
- AI-supported diagnostics

CUSTOMER SATISFACTION — GROWTH — EFFICIENCY

Driving growth through specialty, partnerships and M&A, and consumer-centric solutions

DIAGNOSTICS

Specialty innovation accelerates growth, insights, and patient impact

$2B in annual revenue with strong growth rates[1,2]

15%	25%	15%	10%
ONCOLOGY	NEUROLOGY	AUTOIMMUNE	WOMEN'S HEALTH

- Specialty market growing **3x** faster than broader U.S. diagnostics market
- **50%+** higher tests per requisition when a specialty test is ordered[3]
- Unique ability to scale specialty diagnostics

1. H1 2026 revenue annualized.
2. Percentage growth rates are 2022-2025 revenue CAGR; includes organic and inorganic growth; figures are rounded.
3. Compared to Labcorp's average tests per requisition.

M&A and partnerships drive meaningful, sustainable growth

$900M in revenue from over 30 deals[1]

LEGACY HEALTH
Oregon Providence
BioReference
BalladHealth
Baystate Health
Incyte Diagnostics
ECL Empire City Laboratories
CHS Community Health Systems
NCH
Enzo
California Providence
inspira Health Network
Tribal Diagnostics
North Mississippi Health Services

1. Reflects acquired revenue from 2023-2025; figures rounded.

DIAGNOSTICS

Delivering value for health system partners

Renewals & service excellence

NOVANT HEALTH

UHealth UNIVERSITY OF MIAMI HEALTH SYSTEM

DEPARTMENT OF DEFENSE UNITED STATES OF AMERICA

Reference & lab management expertise

Health Systems Leadership Hub

Lab management expertise & benchmarking

Digital & analytics experiences

labcorp | Diagnostic Assistant®

Insight Analytics

Epic Aura

Innovative collaborations

FOX CHASE CANCER CENTER TEMPLE HEALTH

Children's Hospital of Philadelphia

DIAGNOSTICS

Consumer-centric experiences broaden access to care

GROW CONSUMER TESTING

Marker™
by labcorp

SIMPLIFY DIGITAL EXPERIENCES

PARTNER WITH CONSUMER-FORWARD COMPANIES

ancestry

23andMe

Midi

one medical

DECENTRALIZE DIAGNOSTICS AND EXPAND ACCESS

Delivering value & impact through integrated care partnerships

RWJBarnabas HEALTH

"What began as a trusted partnership, including critical collaboration during the COVID-19 pandemic, has evolved into a ***strategic relationship that advances diagnostics, oncology and precision medicine*** *across RWJBarnabas Health. Together, we are improving access to advanced testing and enhancing patient care."*

John Doll,
Chief Operating Officer, RWJBarnabas Health

Optum

"At the heart of our collaboration with Labcorp is a shared commitment to patients, using AI and data to make care smarter and more connected. Labcorp's role as a preferred network lab gives our providers and members strong access to essential services, and together we're going further, ***applying AI and analytics to accelerate innovation and deliver better outcomes*** *for the people we serve."*

Sandeep Dadlani,
Chief Executive Officer, Optum Insight

one medical

"By making laboratory testing more seamless within the One Medical experience and supporting Amazon Health's efforts to simplify access to care, we're ***reducing friction for patients and enabling a more convenient, connected healthcare journey****."*

Andrew Diamond, MD, PhD
Chief Medical Officer, One Medical

Key takeaways

Large, growing market supported by long-term tailwinds

Technology amplifies the power of our scale, infrastructure and diagnostics expertise

Multiple growth opportunities across specialty diagnostics, partnerships and consumer-centric solutions

Harnessing science and diagnostic insights to shape the future of healthcare

INVESTOR DAY 2026

Biopharma Laboratory Services: Powering the future of drug development

Brian Caveney, MD
President, Biopharma Laboratory Services and Chief Medical and Scientific Officer

labcorp | INVESTOR DAY 2026

Overview

Advancing innovation from discovery to commercialization

Strong financial track record and outlook, with favorable market tailwinds

Fully integrated drug development laboratory capabilities

BLS and Diagnostics: a powerful combination creating greater client value

Advancing innovation from discovery to commercialization

Shared expertise across research and development, medical affairs, science and technology, and data sciences

EARLY DEVELOPMENT LABORATORIES | CENTRAL LABORATORY SERVICES | DIAGNOSTICS

DISCOVERY → PRE-CLINICAL → CLINICAL TRIAL SUPPORT → COMMERCIALIZATION → DIAGNOSTICS

1,200 Scientists and physicians[1]	**100+** Innovative tests launched / year	**1,000** Publications and presentations[2]	**100+** Countries served globally

1. All figures are for 2025, rounded.
2. Includes journal articles, abstracts, posters, peer-reviewed publications and presentations.

Strong track record of growth targeting a large global market opportunity

BLS REVENUE GROWTH



MARKET TAILWINDS

- Strong R&D Pipelines
- Increasing Trial Complexity
- Globalization of Trials
- Expansion of Specialty Therapeutic Areas

1. Midpoint of FY 2026 guidance previously issued on July 30, 2026; see appendix for more information.

Case study: BLS delivers measurable outcomes for trial sponsors



REDUCED COMPLEXITY

HIGH-QUALITY DATA

ACCELERATED CLINICAL DEVELOPMENT

Trusted partner for leading pharma and biotech companies for 40 years

Integrated platform delivering comprehensive laboratory services for clinical trials



Global Client Delivery organization effectively oversees all aspects of operations

Competitive advantages today. Positioned to lead tomorrow.

SCALE

5 Central Labs - United States, Switzerland, China, Singapore, Japan

World's largest automated kit production network

Global expansion

SCIENCE

85% FDA drug and therapeutic product approvals supported[1]

Expertise and capabilities aligned with pharma investment in specialty segments growing **35%+**[2]

Oncology and neurology comprise **>50%** of studies[3]



INNOVATION

Study start-up acceleration

Labcorp Global Trial Connect™

AI-enabled digital pathology

Labcorp Patient Insights Engine

Global network and advanced capabilities supporting clinical trials spanning 100+ countries

1. Source: FDA NME.
2. Source: Citeline, Evaluate pharma, Alzheimer's Association.
3. Source: Labcorp internal metrics, 2025.

BLS and Diagnostics: Complementary strengths, greater client value

Increased trial protocol complexity and data-rich requirements align well with Labcorp's capabilities

PATIENT RECRUITMENT	DECENTRALIZED AND HYBRID TRIALS	END-TO-END TESTING CAPABILITIES
Combined data to identify and engage eligible patients	**Expanding trial access with local and at-home sample collection**	**Testing from discovery to companion diagnostic (CDx) commercialization**
175M+ patient encounters[1]	**2,200+** patient service centers (PSCs)	**130+** active CDx studies spanning **50** biomarkers
>50B test results	**50%** Y/Y growth in clinical trials supported through PSCs[2]	**10%** CDx revenue growth Y/Y[2]
75M contactable patients		

1. Represents an annual metric. Source: Labcorp internal metrics, 2026.
2. Labcorp internal metrics, 2024-2025.

Key takeaways

Global leader with market tailwinds and competitive differentiation

Unique scientific enterprise spanning discovery, development and commercialization

Long-term partnerships driving revenue growth and margin expansion

Laboratory innovation and scale powering the future of drug development

Break

INVESTOR DAY 2026

Specialty Diagnostics: Transforming innovation into access

Shak Ramkissoon, MD, PhD
Senior Vice President, Enterprise Oncology and Diagnostics Medical Affairs

labcorp | INVESTOR DAY 2026

Overview

A proven engine translating innovation into real-world impact

Leading in high-growth specialty areas; oncology deep dive

Unifying the healthcare ecosystem to expand access to precision care

A continuous cycle of innovation and insights powering specialty diagnostics

1 **DISCOVER AND DEVELOP**

Biomarker insights that unlock opportunities for novel diagnostics and precision therapies

2 **VALIDATE AND GENERATE EVIDENCE**

Global clinical trials transforming biomarker potential into clinical proof

3 **SCALE AND COMMERCIALIZE**

Expanding access through diagnostic innovation and test deployment

4 **DELIVER REAL-WORLD IMPACT**

Improving care through broad access

Accelerating specialty leadership in high-impact therapeutic areas

NEUROLOGY

Leading innovation in neurological diagnostics

AUTOIMMUNE

Advancing precision management for chronic conditions

WOMEN'S HEALTH

Delivering personalized insights across life stages



ONCOLOGY

Expanding access to biomarker-driven care

Deep Dive

Neurology | Leading blood-based innovation across many neurological conditions

>150M people living with dementia worldwide by 2050[1]	**<1** neurologist per 100K people globally[2]

ALZHEIMER'S IMPACT ACROSS DIAGNOSTICS AND BIOPHARMA[3]

10
Biomarkers introduced in the past five years

496
Clinical trial protocols supported

>350K
Patients tested in 2025



1. Steinmetz J. et al. The Lancet Neurology, 2024; 23, 344-381
2. Dementia workforce: neurologists (per 100,000)
3. Internal data

Autoimmune | Advancing precision care for chronic conditions

15M Americans affected by autoimmune disorders[1]

1 in 3 autoimmune patients have multiple autoimmune conditions[1]

3 to 5 years; time it can take to diagnose an autoimmune condition[2]

SELECT CONDITIONS

- Rheumatoid arthritis
- Lupus
- Sjögren's Disease
- Myositis

COMPREHENSIVE CAPABILITIES ACROSS AUTOIMMUNE CONDITIONS

Diagnostic and disease activity	Therapeutic drug monitoring	Monitoring and surveillance	Allergy testing
Sjögren's Plus Vectra®	DoseASSURE™	ANA 10	Alpha-gal

Select Tests

1. Abend AH, He I, Bahroos N, et al. Estimation of prevalence of autoimmune diseases in the United States using electronic health record data. Journal of Clinical Investigation. 2025;135(4):e178722.
2. AARDA Survey Study Report. 2017.

Women's Health | Delivering personalized insights across life stages

KEY HEALTH NEEDS

17M women in the U.S. are overdue for at least 1 recommended cancer screening[1]

8M women eligible for BRCA screenings have not been tested[2]

8M women in the U.S. with menopausal conditions are not receiving care[3]

LABCORP ADVANTAGE

650+ Tests across women's health

INVITAE Inheritest® MaterniT® Market-leading genetics

170 Genetic counselors

1. Spencer JC et al., Breast, Cervical, and Colorectal Cancer Screening Rates in Women Aged 45–64 Years, JAMA Network Open (2026), based on 2024 BRFSS data (figure includes Colorectal and Cervical cancer screening gap estimates only).
2. Journal of Internal Medicine, March 2026.
3. Carter, B. Women in Menopause Often Go Untreated. AARP Public Policy Institute, 2025.

Oncology Deep Dive

Cancer care has dramatically evolved over the years, but access to therapies remains a challenge

18M[1]

people **in the U.S.** living with history of cancer

20M[2]

new cancer diagnoses **globally** per year

>60%[3]

of patients with advanced cancers do not receive guideline-based comprehensive biomarker testing

1. ACS Cancer Treatment and Survivorship Statistics, 2025.
2. WHO/IARC GLOBOCAN. New report on global cancer burden in 2022 by world region and human development level; 2024.
3. Chehade CH, Jo Y, Ozay ZI, et al. Utilization and timing of first tumor next-generation sequencing testing (NGS) in patients (pts) with five most common cancers in the USA. DOI: 10.1200/JCO.2025.43.16_suppl.11014. Abstract # 11014. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago.

At the intersection of diagnostics and care delivery, Labcorp accelerates patient access to precision therapies to improve outcomes

80% of U.S. FDA-approved oncology therapies in 2025 were supported by our Biopharma Laboratory Services

DISCOVER AND DEVELOP

VALIDATE AND GENERATE EVIDENCE

DELIVER REAL-WORLD IMPACT

>65%

of U.S. oncologists rely on our diagnostic testing services[1]

SCALE AND COMMERCIALIZE

450+

oncology tests across the continuum of care for all cancer types[1]

1. FY 2025 diagnostic order history.

Broad test menu spanning the continuum of care across indications enables a holistic view of the patient’s disease to inform treatment decisions

PRECISION ONCOLOGY
- Tissue-based molecular tumor profiling
- Hereditary cancer screening panels
- Liquid biopsy
- Whole genome-based MRD
- Integrated blood cancer diagnostics
- Kitted CDx assays

BIOMARKER-DIRECTED
- Molecular (NGS, qPCR)
- AI-enabled digital pathology
- Immunohistochemistry (IHC)
- Cytogenetics, FISH
- Flow cytometry
- Pharmacogenomics

CLINICAL
- HPV, PSA
- Cancer screening tests
- Liver and kidney function tests
- Serum markers
- CBCs
- Metabolic panels

9,200+ patient access points | **EMR/EHR solutions (e.g. Epic Aura)** | **AI-enabled Test Finder**

Customer-driven innovation that advances care, simplifies workflows and drives durable growth

Defining the next generation of oncology care

TISSUE MOLECULAR PROFILING

Genome-wide analysis (DNA + RNA)
Predictive algorithms

LIQUID BIOPSY

Clonal hematopoiesis
ctDNA fraction



HEME MALIGNANCY PROFILING

Whole genome sequencing
Heme MRD

HEREDITARY CANCER

Comprehensive somatic and germline, polygenic risk scores (PRS)

DIGITAL PATHOLOGY

Biomarker screening
Predictive algorithms

KITTED ASSAYS

CDx claims expansion
Expand access U.S., EU, APAC



MOLECULAR RESIDUAL DISEASE

Ultrasensitive tumor-informed
Tumor naïve MRD

Labcorp Plasma Detect Genome MRD
14-day turnaround for baseline testing for earlier treatment optimization

Only 10% - 20% of patients benefit from adjuvant chemotherapy, underscoring the need for better risk stratification



*Circulating tumor DNA (ctDNA): DNA from cancer cells released into the bloodstream.

CONFIDENCE IN RISK STRATIFICATION

High sensitivity & specificity in detecting ctDNA	14-day turnaround for baseline testing

Results from Labcorp Plasma Detect Genome MRD are prognostic and improve current risk stratification

POST-SURGERY

82%
of clinically high risk ctDNA-positive patients have recurrence within 3 years

7%
of clinically low risk ctDNA-negative patients have recurrence within 3 years

SURVEILLANCE

77%
sensitivity for detection of recurrence prior to radiographic imaging

7.6
months before disease is detected clinically

MRD detection post-surgery was associated with an increased risk of disease recurrence



Patients at risk

	0	6	12	18	24	30	36
ctDNA-negative	181	179	172	161	146	107	86
ctDNA-positive	28	25	17	14	10	10	7

Alarcon et al., Clinical validity of post-surgery circulating tumor DNA testing in stage III colon cancer patients treated with adjuvant chemotherapy: The PROVENC3 study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6559.

Advancing MRD detection to identify recurrence earlier and inform care sooner

Plasma Detect Genome MRD
DETECTS 50 PPM[1]



>10-fold improvement

Assay enhancements

Ultrasensitive sequencing chemistry

Improved bioinformatics

Plasma Detect Genome MRD Ultra
DETECTS 3 PPM[1]



1. Source: Internal data

SPECIALTY DIAGNOSTICS

Labcorp Plasma Detect Genome MRD Ultra

A differentiated WGS platform built for scale, adoption and patient impact

Colon	Lung	Breast	Head & Neck	Muscle-invasive Bladder	Ovarian
Stage II - III	Stage I - III	Stage II - III	Stage II - IV	Stage II - III	Stage I - IV

ENHANCED SENSITIVITY | RAPID TURNAROUND | ROBUST EVIDENCE GENERATION

Key takeaways

Deep insights bridging innovation, diagnostics and care delivery to expand access to personalized therapies

A comprehensive portfolio positioned in high-growth specialty markets with durable long-term growth potential

A differentiated ecosystem accelerates precision medicine and guideline-based patient care

INVESTOR DAY 2026

Technology and Innovation: Shaping what's next in healthcare

Bola Oyegunwa, PhD
Chief Information and Technology Officer

Overview

Technology is reshaping what's possible in healthcare

Labcorp is embedding advanced technology across the business

Technology is creating simpler, more connected customer experiences

Automation and AI are driving productivity at scale

Technology is enabling new ways to operate, innovate and compete

Diagnostics and Biopharma Laboratory Services are poised for transformation

Advanced technologies will accelerate breakthroughs in Labcorp's core businesses

- Agentic AI systems for clinical workflows
- AI-enabled drug development
- Parameter optimization (Quantum machine learning)
- Digital twins and spatial computing
- Biomedicine quantum computing accelerators

Drug development acceleration

Identification of new therapies

Discovery of new biomarkers

Actionable data insights that improve patient care

Labcorp embeds advanced technologies across our business

Technology is improving customer experiences, enhancing productivity and transforming operations

IMPROVING CUSTOMER EXPERIENCES	ENHANCING PRODUCTIVITY	TRANSFORMING OUR BUSINESS
Revenue growth	Profitable growth	Competitive advantage

Enhancing the provider experience to improve patient care

Reducing administrative burden and enabling faster, more informed clinical decisions

Broaden access to our test menu
Expedite health system access to specialty and core testing

Epic Aura

Simplify the test order experience
AI driven, test search and clinical decision support tools

Test Finder

Enhance clinical workflows
Orders in progress and order tracking

Support clinical decision making
Empower care decisions with insights and longitudinal trends

labcorp | Link®

labcorp | Diagnostic Assistant®

Empowering people with personalized, connected care experiences

MyLabcorp makes accessing, managing, and navigating care simple and intuitive

Schedule appointments and lab services
Convenient scheduling and proactive reminders

Review and analyze results
Delivers answers and insights across multiple visits

Provide patient education
Empowers care discussions through accessible health information

Enabling faster study execution and better trial outcomes

Accelerating end-to-end study execution through digital workflows, intelligent automation and operational insights

- **Digitize sponsor and investigator workflows**
- **Provide operational intelligence**
- **Accelerate patient recruitment**

GLOBAL TRIAL CONNECT™



Deploying multi-agentic systems at scale to enhance productivity

Intelligent automation enables faster, more efficient operations at scale

LAB OPTIMIZATION

Orchestrating laboratory operations to improve throughput, quality and scalability

REVENUE CYCLE MANAGEMENT

Optimizing revenue operations to improve productivity, accuracy and financial performance

PATIENT SERVICES

Intelligent patient engagement improving access, personalization and service resolution

Powering the next generation of enterprise capabilities

AI innovation platform that rapidly scales innovation into competitive advantage

LABCORP BUILD™

Labcorp's AI platform accelerates enterprise innovation by enabling the secure, governed development of digital capabilities

- **Scientific discovery**
- **Revenue cycle management (RCM)**
- **Contact center**
- **Accessioning**
- **BLS study acceleration**

Extracting actionable intelligence from health data

Moving beyond episodic diagnostic results to intelligent insights that transform care

PROVIDERS

Next test recommendation

Case finding

BIOPHARMA

Pharma data product

Clinical trial matching

PATIENTS & CONSUMERS

Lifestyle management

Intelligent patient report

LABCORP R&D

Reporting enhancement

Discovery and reclassification

Key takeaways

Technology is accelerating revenue growth by improving provider, patient and biopharma experiences

AI is embedded across Labcorp to improve productivity and increase operating leverage

Automation drives long-term operational performance

Labcorp's proprietary data, science and AI platform create a durable competitive advantage

INVESTOR DAY 2026

Long-Term Financial Outlook

Julia Wang
Chief Financial Officer

Overview

Proven track record of delivering on our financial commitments

Durable topline growth driven by clear strategy and focused execution

Sustainable margin expansion supported by topline growth and technology-enabled operating efficiencies

Compelling long-term outlook with 5% - 8% revenue CAGR and 8.5% - 11.5% adjusted EPS CAGR

Strong cash flow generation and disciplined capital deployment driving long-term shareholder value

Continued momentum supports strong 2026 outlook

Reiterating our FY 2026 financial guidance[1]

REVENUE	ADJUSTED EPS	FREE CASH FLOW
$14.71B - $14.83B	**$18.10 - $18.55**	**$1.24B - $1.36B**
+5.4% to +6.3% Y/Y	+10.1% to +12.8% Y/Y	+2.8% to +12.8% Y/Y
Midpoint	*Midpoint*	*Midpoint*
$14.8B	**$18.33**	**$1.3B**
+5.9% Y/Y	+11.5% Y/Y	+7.8% Y/Y

1. Revenue guidance includes impact from foreign currency translation of 0.4% for enterprise and 1.5% for BLS. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends. Guidance unchanged from what was provided on 7/30/2026; revenue and free cash flow rounded to one decimal.

Proven track record of driving consistent and profitable growth

Delivering on long-term outlook from 2023 Investor Day



1. Midpoint of FY 2026 guidance previously issued on July 30, 2026; see appendix for more information.
2. Free Cash Flow from continuing operations excluding spin-related items.

Delivering superior total shareholder returns over time

LH has outperformed the S&P 500 Healthcare index



Longer-Term: immediately before COVID to date.



Prior Outlook: 2023 Investor Day Outlook period to date.

Disciplined capital deployment fueling growth and shareholder value

Balanced between reinvesting in the businesses and returning to shareholders

$6.1B
2023 – 2025 Cash Generated from Operations and Strategic Actions[1]

$6.1B
2023 – 2025 Capital Deployment[2]

$3.7B
Reinvested in the Businesses

$2.4B
Returned to Shareholders

$1.4B
CapEx

$2.3B
M&A[3]

$0.7B
Dividends

$1.7B
Share Repurchases

1. Strategic actions refer to the cash provided by discontinued financing activities from the spin-off of Fortrea in 2023, which was comprised primarily of the $1.6B cash distribution to Labcorp offset by the balance sheet cash of the spun entities.
2. Excludes cash inflows and outflows associated with debt refinancing.
3. M&A includes acquisitions of businesses and purchases of equity affiliates and other investments, offset by proceeds of any sales.

We will continue to maintain discipline in our capital deployment strategy

2027 – 2029 Illustrative capital deployment: invest into the business, strengthen the portfolio and return to shareholders

$6.3B - $7.2B
Operating Cash Flow

REINVEST IN THE BUSINESSES

Capital Expenditures

Anticipated to be ~4% of revenue

M&A

Driving 1.5% - 2.5% revenue CAGR

RETURN CAPITAL TO SHAREHOLDERS

Dividends

Targeted range of 15% - 20% of adjusted earnings

Share Repurchases

Strategic lever to return capital to shareholders covering share dilution at a minimum

Durable topline growth powered by organic growth and M&A

Multiple pathways to drive sustainable long-term growth

5.0% - 8.0%
Revenue Growth
2026 – 2029 CAGR

Organic Growth
3.5% - 5.5%

Key Growth Drivers
- Growing healthcare demand and diagnostic innovation
- Focus on high-growth specialty areas across Diagnostics & BLS
- Strategic partnerships with health systems and leading pharma

M&A
1.5% - 2.5%

Strategic Considerations
- Accelerates growth priorities
- Adds differentiated capabilities
- Strengthens market leadership

Target Financial Criteria
- Accretive to **adjusted EPS** by **year 1**
- Returns **Cost of Capital** by **year 3**

Sustainable margin expansion enabled by topline growth and productivity

Leveraging advanced technologies to drive innovation and efficiencies

75 - 150 bps
Margin Expansion
by end of 2029

Key Drivers

Capture operating leverage
- Deliver durable volume growth
- Drive favorable mix

Generate productivity savings through LaunchPad ($125M - $150M per year)
- Reshape the core and realize acquisition synergies
- Improve operating efficiencies for end-to-end value delivery

Embedding advanced technologies across the enterprise to increase operating leverage and enhance productivity

2026 – 2029 Outlook: positioned for continued strong growth

Compelling revenue growth, margin expansion and cash flow generation driving long-term shareholder value

ENTERPRISE REVENUE	**5.0% - 8.0% CAGR**
Organic Revenue	**3.5% - 5.5% CAGR**
Diagnostics	*2.5% - 4.5% CAGR*
BLS	*4.0% - 7.0% CAGR*
Acquisition Revenue	**1.5% - 2.5% CAGR**

MARGIN EXPANSION	**75 - 150 bps by the end of 2029**
ADJUSTED EPS	**8.5% - 11.5% CAGR**
FREE CASH FLOW	**In line with adjusted earnings growth**

KEY ASSUMPTIONS

- Outlook incorporates potential return of PAMA
- Outlook assumes foreign exchange rates as of June 30, 2026
- Financial leverage: 2.5x to 3.0x gross debt to TTM adjusted EBITDA
- LaunchPad savings of $125M - $150M per year
- Adjusted effective tax rate of approximately 23%
- Includes estimated impact from anticipated capital deployment

Key takeaways

Proven track record of delivering consistent and profitable growth

Durable topline growth and sustainable margin expansion driven by clear strategy and focused execution

Compelling long-term outlook with 5%-8% revenue CAGR and 8.5%-11.5% adjusted EPS CAGR

Strong cash flow generation enables disciplined capital deployment and drives shareholder value while maintaining investment-grade rating on debt

Break


labcorp
INVESTOR DAY 2026
Driving growth and value through
SCIENCE & INNOVATION

The Case for Labcorp

- ✓ Consistent track record of delivering strong performance
- ✓ Tremendous growth opportunities ahead
- ✓ A differentiated platform powered by science, technology and global scale
- ✓ Compelling long-term outlook


labcorp
INVESTOR DAY 2026
Driving growth and value through
SCIENCE & INNOVATION

Appendix

labcorp | INVESTOR DAY 2026

Guidance for 2026

Labcorp is affirming 2026 full-year guidance, last updated on July 30, 2026. The following guidance assumes foreign exchange rates effective as of June 30, 2026. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends.

	2026 Guidance	
	Low	High
Revenue		
Labcorp Enterprise[1,2]	$14,710	$14,827
Growth[3]	5.4%	6.3%
Diagnostics Laboratories	$11,450	$11,532
Growth[3]	5.3%	6.0%
Biopharma Laboratory Services[4]	$3,269	$3,300
Growth[3]	5.5%	6.5%
Adjusted EPS	$18.10	$18.55
Free Cash Flow	$1,240	$1,360

1. 2026 Enterprise guidance includes an impact from foreign currency translation of 0.4%.
2. Enterprise level revenue is presented net of intercompany transaction eliminations.
3. Growth based on 2025 Enterprise revenue of $13,952 million, Diagnostics Laboratories revenue of $10,876 million and Biopharma Laboratory Services revenue of $3,098 million.
4. 2026 Biopharma Laboratory Services guidance includes an impact from foreign currency translation of 1.5%.